Rentokil shares jump as US turnaround lifts outlook

Rentokil Initial PLC shares surged nearly 11% after the company reaffirmed its full-year outlook and reported improving trends in its crucial North American market. Despite a first-half adjusted profit before tax decline of 8.7% to $418 million on 3.1% revenue growth, North American organic growth accelerated to 1.6% from 0.5% in Q1, with pest control services returning to positive growth and lead flow improving. While analysts maintained 'hold' ratings citing ongoing integration challenges and potential delays to the post-2026 North American margin target, the market reacted positively to these operational green shoots, signaling confidence in the region's recovery.

Analysis

Rentokil Initial PLC's shares experienced a significant rally of nearly 11% following the reaffirmation of its full-year outlook and nascent signs of a turnaround in its critical North American division. Despite a decline in first-half adjusted pre-tax profit by 8.7% to $418 million and margin compression to 15.2%, investors focused on forward-looking operational metrics. Specifically, North American organic growth accelerated to 1.6% in the first half from 0.5% in the first quarter, with the region's pest control services returning to positive territory with 0.3% growth. This momentum is further supported by a 6.6% increase in lead flow for residential and termite services in June, marking the first monthly gain of the year. However, analysts from Peel Hunt and Stifel maintain 'hold' ratings, signaling caution. While they acknowledge these encouraging trends, they also point to potential delays in the full integration of the Terminix business, which could impact the timeline for achieving the targeted North American adjusted operating margin of over 20% post-2026. The company's valuation, at a forward EV/EBITDA multiple of 10.2x, is seen by analysts as a fair price for these near-term challenges balanced against the long-term synergy potential.

Key Decisions for Investors

• Investors should weigh the positive operational momentum in North America, evidenced by accelerating organic growth and improving lead flow, against the reported 8.7% decline in first-half profit.
• Monitor future announcements regarding the Terminix integration, as analysts have flagged that 'refined timelines' may delay the achievement of the post-2026 margin targets, representing a key execution risk.
• Given the 'hold' ratings and a valuation that analysts consider fair for the near-term challenges, it may be prudent to await further evidence of sustained recovery and margin improvement before significantly altering positions.
• The maintained interim dividend and reaffirmed full-year guidance provide a degree of stability, which should be factored into any assessment of downside risk.